InspireMD Inc is the United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Quote | InspireMD Inc. (NASDAQ:NSPR)
Last: | $3.35 |
---|---|
Change Percent: | 0.9% |
Open: | $3.4 |
Close: | $3.32 |
High: | $3.42 |
Low: | $3.244 |
Volume: | 63,530 |
Last Trade Date Time: | 07/30/2024 03:00:00 am |
News | InspireMD Inc. (NASDAQ:NSPR)
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Message Board Posts | InspireMD Inc. (NASDAQ:NSPR)
Subject | By | Source | When |
---|---|---|---|
bears and bulls | Value_Investor | investorshub | 05/14/2023 5:20:14 PM |
$NSPR MomentumIts now last up | Disquisition | investorshub | 05/12/2023 8:59:56 PM |
The trading up | iluvkush | investorshub | 05/10/2023 4:00:25 PM |
Price trading last up | Disquisition | investorshub | 05/10/2023 2:10:52 AM |
Long and strong lets hope im right | Value_Investor | investorshub | 05/08/2023 2:48:36 AM |
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...